Legis Daily

Increasing Access to Biosimilars Act of 2021

USA117th CongressS-1427| Senate 
| Updated: 4/28/2021
John Cornyn

John Cornyn

Republican Senator

Texas

Cosponsors (1)
Michael F. Bennet (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Increasing Access to Biosimilars Act of 2021 This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 116-4134
Increasing Access to Biosimilars Act of 2020
Apr 28, 2021
Introduced in Senate
Apr 28, 2021
Read twice and referred to the Committee on Finance.
Apr 29, 2021

Latest Companion Bill Action

HR 117-2869
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    S 116-4134
    Increasing Access to Biosimilars Act of 2020


  • April 28, 2021
    Introduced in Senate


  • April 28, 2021
    Read twice and referred to the Committee on Finance.


  • April 29, 2021

    Latest Companion Bill Action

    HR 117-2869
    Referred to the Subcommittee on Health.

Health

Related Bills

  • HR 117-2869: Increasing Access to Biosimilars Act of 2021
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceHealth information and medical recordsHealth programs administration and fundingMedicarePrescription drugs

Increasing Access to Biosimilars Act of 2021

USA117th CongressS-1427| Senate 
| Updated: 4/28/2021
Increasing Access to Biosimilars Act of 2021 This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 116-4134
Increasing Access to Biosimilars Act of 2020
Apr 28, 2021
Introduced in Senate
Apr 28, 2021
Read twice and referred to the Committee on Finance.
Apr 29, 2021

Latest Companion Bill Action

HR 117-2869
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    S 116-4134
    Increasing Access to Biosimilars Act of 2020


  • April 28, 2021
    Introduced in Senate


  • April 28, 2021
    Read twice and referred to the Committee on Finance.


  • April 29, 2021

    Latest Companion Bill Action

    HR 117-2869
    Referred to the Subcommittee on Health.
John Cornyn

John Cornyn

Republican Senator

Texas

Cosponsors (1)
Michael F. Bennet (Democratic)

Finance Committee

Health

Related Bills

  • HR 117-2869: Increasing Access to Biosimilars Act of 2021
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceHealth information and medical recordsHealth programs administration and fundingMedicarePrescription drugs